Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

GW Pharmaceuticals moves boss to US

GW Pharmaceuticals moves boss to US
Cannabis growing shed

GW Pharmaceuticals (LON:GWP) is shifting its chief executive to the US to spearhead the company’s overseas development of its cannabis-based drugs.

Justin Gover is moving to GW’s new base in Southern California, where he will oversee the creation of a US business.

It has also appointed the former president of US drug group Allergan’s North American pharmaceutical  division, Julian Gangolli, as the president of its own operation in the region.

GW  commercialised the world's first plant-derived cannabinoid prescription drug, Sativex, which is approved for treating spasticity due to multiple sclerosis in 27 countries outside the US.

It is also developing a childhood epilepsy drug called Epidiolex as well as treatments for pain associated with advanced cancer, glioma, type 2 diabetes and schizophrenia.

It will be hoping to benefit from the increasing liberalisation of cannabis laws in the US, where some states have authorised its use as a medication.

As president of the North American pharmaceutical division of Allergan from 2004 to April this year, Gangolli ran a 1,400-strong commercial operation with sales topping $3.8bn last year.

GW’s chairman Geoffrey Guy said: "As Epidiolex nears its final stages of clinical development and as GW prepares for future US launch, the time is right to start building our in-house US commercial infrastructure.

“Julian's experience at building and running a major US pharmaceutical business built on specialty products will be complemented by the re-location of Justin to the US with his intimate knowledge of GW, its products and pipeline. Together, they will spearhead GW's US growth."


GW is also expanding manufacturing and research & development operations in the UK, where it employs 325 staff, up from 190 two years ago. Shares in GW rose 7.5p or 1.3% to 603.5p at 14:47 in London.

View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use